High-Throughput Sequencing Enhanced Phage Display Identifies Peptides That Bind Mycobacteria by Ngubane, Nqobile A. C. et al.
High-Throughput Sequencing
Enhanced Phage Display Identifies
Peptides That Bind Mycobacteria
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Ngubane, Nqobile A. C., Lionel Gresh, Thomas R. Ioerger, James
C. Sacchettini, Yanjia J. Zhang, Eric J. Rubin, Alexander Pym, and
Makobetsa Khati. 2013. “High-Throughput Sequencing Enhanced
Phage Display Identifies Peptides That Bind Mycobacteria.” PLoS
ONE 8 (11): e77844. doi:10.1371/journal.pone.0077844. http://
dx.doi.org/10.1371/journal.pone.0077844.
Published Version doi:10.1371/journal.pone.0077844
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879035
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
High-Throughput Sequencing Enhanced Phage Display
Identifies Peptides That Bind Mycobacteria
Nqobile A. C. Ngubane1,2, Lionel Gresh1, Thomas R. Ioerger3, James C. Sacchettini4, Yanjia J. Zhang5,
Eric J. Rubin5, Alexander Pym2, Makobetsa Khati1,6*
1 Emerging Health Technologies Platform, Council for Scientific and Industrial Research, Biosciences Unit, Pretoria, Gauteng, South Africa, 2 KwaZulu-Natal Research
Institute for Tuberculosis and Human Immunodeficiency Virus, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa, 3Department of
Computer Science and Engineering, Texas A&M University, College Station, Texas, United States of America, 4Department of Biochemistry and Biophysics, Texas A&M
University, College Station, Texas, United States of America, 5Department of Immunology and Infectious Disease, Harvard School of Public Health, Boston, Massachusetts,
United States of America, 6Department of Medicine, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa
Abstract
Bacterial cell wall components have been previously used as infection biomarkers detectable by antibodies. However, it is
possible that the surface of the Mycobacterium tuberculosis (M. tb), the causative agent of tuberculosis (TB), also possesses
molecules which might be non-antigenic. This makes the probing of biomarkers on the surface of M. tb cell wall difficult
using antibodies. Here we demonstrate the use of phage display technology to identify peptides that bind to mycobacteria.
We identified these clones using both random clone picking and high throughput sequencing. We demonstrate that
random clone picking does not necessarily identify highly enriched clones. We further showed that the clone displaying the
CPLHARLPC peptide which was identified by Illumina sequencing as the most enriched, binds better to mycobacteria than
three clones selected by random picking. Using surface plasmon resonance, we showed that chemically synthesised
CPLHARLPC peptide binds to a 15 KDa peptide from M.tb H37Rv whole cell lysates. These observations demonstrate that
phage display technology combined with high-throughput sequencing is a powerful tool to identify peptides that can be
used for investigating potential non-antigenic biomarkers for TB and other bacterial infections.
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Introduction
TB remains a significant problem worldwide, despite the
widespread availability of effective antibiotics against drug
sensitive M. tb strains. The World Health Organisation (WHO)
estimates that in 2011, there were between 0.8 and 1.1 million
deaths of HIV negative people globally, that resulted from TB [1].
Lack of rapid and accurate diagnostic tools limits the control of
TB.
The absence of sensitive and specific TB detection reagents and
a poor pipeline in biomarker identification significantly limits
improvements in our ability to diagnose TB. One of the most
desirable characteristics of a TB biomarker is its ability to
differentiate patients with active disease from those with latent TB
infection [2]. This may be best achieved by targeting a pathogen-
associated biomarker as current immunological biomarkers are
limited in their application: they are mainly used to detect latent
infection and their specificity can be as low as 42% in high
epidemic countries [3]. Thus far, the only available pathogen-
associated tests that are used on sputum samples are smear
microscopy [4,5], culture [6], and nucleic acid amplification tests
[7,8]. In the case of extrapulmonary TB, or in paediatric and
immunocompromised patients, where individuals would have
difficulty producing a sputum sample, tests that probe for
biomarkers that can be detected in samples other than sputum
are critical. Currently, these include assays that detects lipoar-
abinomannan (LAM) [9,10] in urine, the volatile organic
compounds breath test [11,12], and whole blood culture [13,14].
However, these tests have varying limitations which include low
sensitivity, low specificity or poor cost-effectiveness. Therefore, it is
critical that new biomarkers are identified to improve diagnosis of
TB.
We hypothesize that numerous cell wall associated components
are shed by the mycobacterium during infection. These might
possibly be detected in patient samples such as sputum, serum and
urine, if their suitable probing reagents were available. Antibodies,
which are the conventional reagents used for biomarker probing
or pull-down are limited, because by definition they can only
identify antigenic components. Thus, we employed phage display
technology to identify peptides that can bind surface components
of mycobacteria, regardless of their antigenicity.
Indeed, panning of phage display libraries has successfully
identified peptides that bind intact bacteria [15] and viruses [16].
The technology involves the display of a random peptide sequence
appended to a recombinant viral protein on the surface of a
bacteriophage [17]. The typical selection, named biopanning,
involves exposure of the unselected library to the target, and
removal of unbound phages. The bound phages are then eluted
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and amplified by infection of host bacteria under selective
pressure.
One of the challenging steps in the use of phage display
technology is the identification of the most promising candidates at
the end of the biopanning experiment. The random clone-picking
method is traditionally used to sequence and identify displayed
peptide clones that were enriched during biopanning. Depending
on the sequence diversity at the end of the selection, this method
may not necessarily identify the highly selected clones. However,
high-throughput (HTP) sequencing has made possible the
sequencing of millions of inserts allowing for a higher resolution
of the selected pool of the displayed peptides [18,19].
In this study, we used HTP sequencing to identify enriched
peptide sequences from the biopanning experiment against M. tb.
We employed a library that displays random 7-mer peptides
(CX7C) at the tip of the pIII minor coat protein. The displayed
peptides are flanked by two cysteine residues, which are oxidized
during phage assembly to a disulfide bond, resulting in a loop
constrained peptide. We initially used the traditional clone picking
method to identify the enriched clones. This was followed by
analyzing several rounds of selection through HTP sequencing.
Surprisingly, we found that HTP sequencing not only revealed the
dynamics of the selection but also identified the most abundant
phage clone that was missed by the traditional clone picking
method.
Materials and Methods
Bacterial strains and growth conditions
The bacterial strains used in the study were M. tb H37Rv, M. tb
DleucineD and DpanthothenateCD double auxotroph (Dleu/
Dpan), M. smegmatis mc2, M. bovis BCG and the E. coli ER2738
strain for phage amplification.
Mycobacteria were grown on Middlebrook 7H9 media (Sigma,
St. Louis, MO) supplemented with the Middlebrook oleic albumin
dextrose catalase (OADC) (bovine albumin fraction V 5 g/l,
dextrose 2 g/l, catalase 0.004 g/l, oleic acid 0.05 g/l, sodium
chloride 0.85 g/l) (Sigma, St. Louis, MO). The 7H9 media was
further supplemented with both leucine (50 mg/ml) and pantothe-
nate (24 mg/ml) as previously described [20]. For further use
mycobacteria were centrifuged at 8000 rpm and resuspended in
carbonate buffer (35 mM NaHCO3, 15 mM Na2CO3 [pH 9.8]).
The E. coli ER2738 strain was grown in Luria-Bertani (LB)
medium for amplification of phage. For the plating of the phage
isopropyl b-D-thiogalactopyranoside (IPTG; 1 mM final concen-
tration) and 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside
(X-Gal; 60 mM final concentration) were added to LB agar plates
before plating. All bacterial cultures were grown at 37uC with
agitation.
Immobilization of the target mycobacteria
Mycobacteria suspensions were prepared in carbonate buffer
(35 mM NaHCO3, 15 mM Na2CO3 [pH 9.8]) and adjusted to an
optical density of 1.0 at 660 nm, corresponding to approximately
108 CFU per ml [15]. Maxisorp surface microtiter plate (Nunc,
Roskilde, Denmark) wells were filled with 200 ml of bacterial
suspension and incubated overnight at 4uC. Wells were blocked
overnight at 4uC with gelatin (0.5%) supplemented supernatant of
an E. coli strain ER2738 infected with the whole phage library
[15].
Selection of phage displayed peptides-biopanning
Selection of peptides from a CX7C library was carried out as
previously described [21]. In the first round of panning, 10 ml of
the library (,261011 phages) was diluted to 100 ml with phosphate
buffered saline supplemented with 0.1% Tween-20 (PBST)
(0.01 M phosphate buffer, 0.0027 M potassium chloride and
0.137 M sodium chloride, pH 7.4, 0.1% tween) and incubated in
bacterial-coated wells for 1 h at room temperature with gentle
agitation. Nonbinding phages were then discarded as described by
[21]. In brief, the wells were washed 25 times with PBST followed
by four washes with the low pH elution buffer (0.2 M glycine-HCl,
pH 2.2). Finally, the elution of the bound phage was carried out
using 100 ml the low-pH elution buffer and sonicated in a
sonicator water bath (50 kHz) for 10 minutes. The eluent was then
neutralised with 15 ml of 1 M Tris-HCl, pH 9. In the following
rounds of biopanning an average of 261011 plaque-forming units
(PFU) was used. Five rounds of biopanning were performed. The
first three rounds were targeted against M. tb (Dleu/Dpan),
followed by a subtraction round against M. smegmatis. The fifth
round of positive selection was against the targeted M. tb (Dleu/
Dpan). After the final round of biopanning, single clones were
picked and the random region sequenced using the 296M13gIII
primer (59-CCC TCA TAG TTA GCG TAA CG-39). The
unselected library, round 3, round 4 and round 5 phage pools;
were also subjected to high throughput (HTP) Illumina sequenc-
ing.
Phage Amplification
Eluates were amplified according to manufacturer’s instructions
(New England Biolabs, Beverly, Massachusetts). The phage eluates
were used to infect E. coli ER2738 host cells. After 4.5 h of growth
at 37uC, bacteria were removed by centrifugation and phages in
the supernatant were precipitated by adding one-sixth volume of
20% polyethylene glycol-8000 and 2.5 M NaCl overnight at 4uC.
The precipitate was resuspended in 100 ml of PBS, and amplified
eluates were titered to determine phage concentration.
Phage ELISA
Microtiter plate wells were coated with 100 ml of mycobacteria
suspension, with an optical density of 1.0 at 660 nm in carbonate
buffer (35 mM NaHCO3, 15 mM Na2CO3 [pH 9.8]), and
incubated overnight at 4uC. Plates were blocked overnight at
4uC with 200 ml of the gelatin (0.5%)-supplemented supernatant of
an E. coli strain ER2738 F9 culture infected with the whole phage
library. A separate set of wells were blocked with blocking buffer
without previous mycobacteria immobilization as negative con-
trols (no target control). One hundred microliters of each selected
amplified phage clone in PBS was transferred to coated wells.
Plates were incubated for 1.5 h at room temperature. Wells were
then washed six times with PBST. Horseradish peroxidise (HRP)-
labelled mouse anti-M13 monoclonal antibody (GE Healthcare
UK Ltd, Buckinghamshire, England) was diluted in PBS (1:5,000).
Two hundred microliters of the antibody was added per well and
incubated for 1 h at room temperature. This was followed by
washing the wells six times with PBST. One hundred and fifty
microliters of substrate solution (2,29-azino-di-[3-ethylbenzthiazo-
line sulfonate diammonium salt) (Thermo Scientific, Waltham,
Massachusetts) was added and incubated for 30 min at 37uC. The
reaction was stopped with 100 ml of 1% SDS. Absorbance was
determined using a microtiter plate reader at the wavelength of
405 nm.
Phage DNA preparation and sequencing
The amplification of the displayed peptides was performed with
PCR using primers spanning the variable region in the gp3 phage
coat protein (Table S1). The primers used for amplification
contained homology required for annealing to the Illumina
Phage Display Peptides That Bind Mycobacteria
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sequencing flowcell with the forward primer containing a five-
nucleotide barcode to enable multiplexing. This enabled ampli-
cons to be directly sequenced on an Illumina Genome Analyzer II
as previously described [22]. The PCR reaction mix consisted of
0.5 mM of each primer, and 5 U of the GoTaqH DNA polymerase
mix (Promega, Fitchburg, Winsconsin) in a 100 ml final volume.
Whole phage PCR (denaturation at 95uC for 1 minute, annealing
at 55uC for 2 minutes and extension at 72uC for 1 minute and
30 seconds) was performed as previously described [23]. Cycles
varied from 10 to 25, and the number of reaction tubes varied
from 2 to 5, according to the amount of amplicon available for
each sample. Resulting amplicons (0.45–0.85 mg) were directly
sequenced using the Illumina Genome Analyzer II. The nucleotide
sequence of the amplified region of the gp3 gene was reconstructed
by aligning and combining the two paired-end reads. The 36 bp
variable region was extracted by trimming off constant bases and
was translated into amino acid sequences of length 12 using the
Illumina GA Pipeline software, which were then clustered for
statistical analysis.
Peptide Synthesis
Both peptides (Biotin-ACPLHARLPCG and its scrambled
derivative Biotin-ACHLRPPLACG) were synthesised by GL
Biochem (Shanghai, China), with the C-C disulphide bridge.
The peptides were supplied as a powder with purity above 85%.
Surface plasmon resonance (biosensor) analysis
A BiacoreTM 3000 instrument (GE Healthcare UK Ltd,
Buckinghamshire, England) was used. Instrument temperature
was set to 25uC and HBS-N (10 mM Hepes and. 150 mM NaCl,
pH 7.4) was used as running buffer. 50 mg/ml of streptavidin in
sodium acetate buffer pH4.5, was immobilised by amine coupling
on the CM5 sensor chip (GE Healthcare UK Ltd, Buckingham-
shire, England). Immobilisation was performed at a flow rate of
10 ml/min for 7 min. The biotinylated peptides were captured
using the previously immobilised streptavidin. A total of 60 ml of
100 mg/ml biotinylated-peptide in PBS (sample flow cell) was
loaded onto the chip at the flow rate of 10 ml/min. No prior
streptavidin or peptide was immobilised on the negative control
flow cell. Binding of M. tb H37Rv whole cell lysate to the
biotinylated peptide was then analysed by diluting the lysate in
HBS-N buffer (10 mM Hepes and 150 mM NaCl, pH 7.4) and
passing it over the chip at 10 ml/min. The M. tb H37Rv whole cell
lysate binding was analysed at 100 and 500 mg/ml of total protein
concentrations. While the unrelated bacteria whole cell lysates
were analysed at 100 mg/ml of total protein concentration.
Protease digestion of M. tuberculosis H37Rv lysate
M. tuberculosis H37Rv whole cell lysate was treated with 1 mg/
ml Pronase E (Sigma, St. Louis, Missouri) for 2 hours. The
protease digestion reaction was inactivated by heating at 90uC for
20 minutes. The negative control reaction was treated in a similar
manner in the absence of Pronase E.
Results
Selection of phage displayed peptides binding to intact
M. tb
In order to identify phage displayed peptides that could bind to
intact M.tb, a constrained 7-mer (CX7C) phage library was used
for panning on immobilised DleucineD and Dpanthothenate CD
double auxotroph (Dleu/Dpan) strain of M. tb. This non-
pathogenic M. tb strain was used as a model target because it is
easy to manipulate, as it can be grown outside a biosafety level 3
laboratory. Three positive rounds of panning were performed
against the targeted M. tb Dleu/Dpan strain (Figure 1). In order to
remove peptides binding to cell wall components common to the
mycobacterium genus, a subtraction round (round 4) was
performed against M. smegmatis, which is a related mycobacterium.
A final positive panning round (round 5) was performed to enrich
for peptides that are specific to M. tb (Figure 1). The binding signal
of the selected phage pool after five rounds of panning was
significantly (p,0.05) higher when compared to that of the
unselected library (Figure 2). This data suggests successful
enrichment of clones that bind to mycobacteria.
Characterisation of the enrichment process
In order to evaluate the trend of enrichment during biopanning,
we performed HTP sequencing on the library before selection and
after three, four and five rounds of biopanning. We obtained
approximately 1.5 million sequencing reads for each phage display
selection round, representing 1.366106 unique peptides from the
unselected library (Figure 3A). While this fell short of the
theoretical complexity of the library, 1.236109 heptapeptides, it
represented sufficient depth to measure the quantitative enrich-
ment of relevant peptides. To confirm successful enrichment
during selection, we characterized the reduction in diversity of the
pool in the consecutive rounds of panning. The overall diversity
decreased (Figure 3A) while the frequency of the highly enriched
peptides increased (Figure 3B). To illustrate, the number of unique
sequences decreased from 1,361,688 in the unselected library to
5665 after the final round of panning (Figure 3A). This suggests
that there was enrichment during the panning experiments.
Concurrently, the frequency of the most abundant peptide
(corresponding to phage 1) increased from 0.48% to 81.15% in
round three (Figure 3B), indicating that this peptide was highly
selected for in as early as the third round of selection.
Identification of highly selected phage clones
Ten plaques were selected using the traditional random cloning
picking from the final round of biopanning, and were sequenced.
Sequencing data of four of these plaques were ambiguous. Three
unique sequences were obtained from the six remaining randomly
selected plaques (Table 1). Two clones, phage 2 and phage 3, were
represented more than once (Table 1). HTP sequencing, however,
described a different quantitative landscape. We calculated the
enrichment of every sequenced peptide by performing a Pearson
Chi-squared test, comparing the selected pools to the input library
(Figure 3C). While the proportion of multiple peptides increased in
the selected libraries, a single phage clone displaying the peptide
CPLHARLPC, dominated the selected libraries and was especially
enriched during selection (p-value,102500). Surprisingly, this
clone was not identified using random clone picking (Table 1).
Nonetheless there is still some degree of correlation between the
peptide sequences that were identified by traditional clone picking
and the top five sequences identified using high-throughput
sequencing. That is, all three unique sequences identified during
random clone picking were in the top five of the most abundant
peptides identified by high-throughput sequencing. Moreover,
since the most abundant peptide had a frequency of more than
80% after the first three rounds of selection, this means that with
the current sequencing depth, further rounds of selection will less
likely have lead to the identification of peptides that could not be
found in the current available sequencing data.
To establish whether the selected peptides were not binding to
non-targeted substrates and other components used during the
biopanning process like BSA, we used the web-based server called
Scanner and Reporter Of Target-Unrelated Peptides (SAR-
Phage Display Peptides That Bind Mycobacteria
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OTUP), which can identify non target specific peptides [24]. None
of the four sequences selected were identified as nonspecific
binders to the commons reagents used during selection. However,
phage 1 has recently been isolated and characterised as binding to
the IV.C102 H1N1 monoclonal antibody and the swine-origin
influenza virus A sera [25] (Table 1).
Binding characterisation of the selected recombinant
phages to M. tb
Binding of the selected phage clones was investigated on
immobilised M. tb (Dleu/Dpan) strain (Figure 4B). We further
evaluated the effectiveness of the subtraction round, by
comparing the binding of the selected phages to M. tb (Dleu/
Dpan) strain to that of M. smegmatis (Figure 4C) which was
targeted during the subtraction round. For each amplified clone,
1011 PFU were used in the phage ELISA. Our results showed
that phage 1 which was identified using HTP sequencing and
one out of the three phages identified by random cloning, phage
4, had significantly (p,0.05) higher binding to M. tb as
compared to the unselected library (Figure 3B). Interestingly,
phage 1 and phage 4, in addition to significantly binding to
intact M. tb, also showed significant (p,0.01) binding to M.
smegmatis (Figure 4C). However, phage 2 and 3 which were
respectively identified using random clone picking showed no
significant binding to both M. tb and M. smegmatis as compared
to the unselected library (Figure 4B–C).
Figure 1. Schematic outline of the bio-panning procedure. Three rounds of biopanning were performed against the DleucineD and
DpanthothenateCD double auxotroph (Dleu/Dpan) strain of M. tb. After the third round of panning, eluted phages were subjected to a subtraction
round against M. smegmatis (round 4). Round 5 was performed against the target (Dleu/Dpan) M. tb. DNA from phages eluted at the end of the fifth
round was sequenced and the corresponding peptide sequences were analysed.
doi:10.1371/journal.pone.0077844.g001
Figure 2. Binding of the phage eluates to mycobacteria
species. Comparison of the binding signal of the unselected phage
library to M. tb (Dleu/Dpan) and M. smegmatis to that of the phage
population from the final round of biopanning (Round 5) to the same
species.
doi:10.1371/journal.pone.0077844.g002
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Figure 3. Sequence enrichment profiles after high-throughput sequencing of the phage displayed libraries using Illumina
technology. (A) Number of unique peptides observed in the different rounds of biopanning (B) Frequency of the selected peptides at each round of
biopanning (C) Manhattan plot showing peptide sequence enrichment (GWAS) results for round 3 and 5 of biopanning.
doi:10.1371/journal.pone.0077844.g003
Table 1. Summary of selected phage clones.
Phage Clone
number Percentage representation in the sequenced population
Phage displayed
peptide sequence
SAROTUP: Target Unrelated
Peptide scanner Results
Random picking Method HTP sequencing reads at round 5
Total number
of sequences
Percentage
representation
of clone
Total number of
sequence reads
Percentage
representation
of clone
n % n %
1a,{ 6 0 1 655 954 82.49 CPLHARLPC Anti-influenza A H1N1
monoclonal antibody IV.C102
and SIV sera from patients
(Zhang et al., 2011)
2a,b 6 16.67 1 655 954 0.81 CHYDGARAC None found
3a,b 6 33.33 1 655 954 0.92 CDHGYLPSC None found
3a,b 6 50.00 1 655 954 5.05 CFDTRSLVC None found
aClones identified in the top ten highly enriched sequenced by HTP sequencing.
bClones identified through random sequencing.
{The highest enriched clone at round 5, as identified by HTP sequencing.
doi:10.1371/journal.pone.0077844.t001
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Binding characterisation of the highly enriched, HTP
sequencing identified Phage 1
The highly enriched recombinant phage 1 was further
investigated on its ability to bind the pathogenic strain of M. tb
H37Rv, using ELISA. To evaluate whether the selected phage
could discriminate between bacteria from the same genus of
mycobacterium, we further characterised its binding specificity
by comparing its binding to M. tb and to other mycobacterium
species namely, M. smegmatis, M. bovis BCG and the M. tb
(Dleu/Dpan) strain. Our results show that phage 1 consistently
bound to all the three mycobacterium species tested, which
included two strains of M. tb, with a binding signal that was at
least twice as high when compared to the phage library which
was used as a control (Figure 5A–D). These results were
consistent when tested using two different phage inputs of
561011 and 161012 PFU. This phage showed no significant
difference in binding the pathogenic strain M. tb H37Rv, M. tb
(Dleu/Dpan) or M. smegmatis. Notably, there was a significantly
(p,0.01) higher binding signal to BCG as compared to M. tb
H37Rv.
Binding of the synthetic peptide displayed by phage 1 to
M. tb H37Rv lysate
In order to test whether the highly enriched displayed peptide
can bind its ligand when it is not displayed by the carrier phage,
the peptide CPLHARLPC (phage1-synpeptide) and its scrambled
derivative CHLRPPLAC (phage1-synpeptide-Sc) were synthesised
with a biotinylation modification. The binding of the synthesised
peptides to the whole cell lysate from M. tb H37Rv was evaluated
using the biacore SPR technology. Biotinylated peptides were
immobilized on a streptavidin sensor chip (Figure 6A) and whole
cell lysates were injected at different concentrations of total
protein. When evaluating the binding of the synthesized peptides
to different concentrations of M. tb whole cell lysate, we found that
there was a 25% increase in binding signal of phage1-synpeptide
when the total protein concentration of the lysate was increased by
Figure 4. Binding of the selected phage clones to mycobacteria species. (A) M. tb (Dleu/Dpan), (B) M. smegmatis. A two-tailed, unpaired t-
test was used to analyse significance (**p,0.01 and *p,0.05). Error bars represent standard deviations of the arithmetic means of the normalised
optical densities at 405 nm performed in triplicates.
doi:10.1371/journal.pone.0077844.g004
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5 fold from 100 mg/ml to 500 mg/ml. In contrast, there was no
notable difference in the binding signal of the scrambled
derivative between the two concentrations (Figure 6B). This
data suggests that, Phage1-synpeptide binds more strongly to
H37Rv whole cell lysate than its scrambled derivative. To
further evaluate specificity of the selected peptides, we measured
their binding signal to whole cell lysates from unrelated bacteria.
All bacteria strains tested which included both Gram negative
and Gram positive bacteria that are potential upper respiratory
pathogens and an E. coli strain used for the amplification of
phage during biopanning, had binding signal similar to that of
the negative control, which had no prior peptide immobilisation
(Figure 6C–F). This data is indicative of the specificity of the
selected peptide to binding mycobacteria.
Characterisation of the mycobacteria cell wall associated
binding partner for Phage1 synthetic peptide (phage1-
synpeptide)
To determine if the mycobacteria target of phage 1 displayed
peptide is a protein, we tested its binding to protease-treated M.
tuberculosis whole cell lysate. Our results showed that the binding of
phage1-synpeptide to M. tuberculosis whole cell lysate is abrogated
after the lysate has been incubated for 2 hrs with Protenase E
(Figure 7). This data suggests that phage1-synpeptide binding
partner is likely to be of a peptide or protein nature.
In order to validate that mycobacteria protein interacts with the
phage 1 displayed peptide, we performed a pull down assay from
M. tuberculosis H37Rv whole cell lysate using phage1-synpeptide as
a capture peptide. The scrambled derivative, phage1-synpeptide-
Sc, and the streptavidin beads without prior immobilisation of the
phage 1 peptide were used as negative controls. A protein of
approximately 15 kDa in size was pulled down from M. tuberculosis
whole cell lysate by phage1-synpeptide and was not detectable on
the PAGE gel using Coomassie staining on both negative control
experiments (Figure 8). The absence of the pulled down peptide
when phage1-synpeptide-Sc (Figure 8) was used as capture
molecule, is indicative of the specific nature of the interaction
between the phage 1 displayed peptide and its mycobacteria
binding partner.
Discussion
In this study, we applied phage display technology with the aim
of searching for peptide ligands that bind to M. tb, and can be later
developed to probe for potential biomarkers in patients’ clinical
samples. We evaluated four phage clones that were identified from
the panning of a loop-constrained heptapeptide (CX7C) library
against M. tb. Both HTP sequencing and random clone picking
revealed multiple peptides that were enriched during selection.
However, only with HTP sequencing were we able to calculate
quantitative measures of enrichment, which allowed us to compare
Figure 5. Characterisation of the Phage 1 clone identified using HTP Illumina sequencing. Phage 1 was amplified and 561011,
161012phages (x-axis) were used for a plate binding assay with (A) M. tb H37Rv, (B) (Dleu/Dpan) M. tb, (C) BCG and (D) M. smegmatis as solid-phase
antigens. The unselected library was used as a control. A two-tailed, unpaired t-test was used to analyse significance (**p,0.01). Error bars represent
standard deviations of the arithmetic means of the normalised optical densities at 405 nm performed in triplicates.
doi:10.1371/journal.pone.0077844.g005
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and to rank our multiple hits. We found that our most enriched
peptide which was identified only by HTP sequencing had the
highest binding signal to Mtb when compared to all of the
randomly selected clones and the unselected library. A single
phage clone, phage 1, displaying the peptide CPLHARLPC, was
significantly enriched during the selection. Interestingly, the
traditional random clone picking method failed to identify this
clone, despite the fact that HTP sequencing showed that this clone
represented over 80% of the sequenced population after the first
three rounds of selection (Figure 3B). This result is in agreement
with earlier findings showing that when comparing HTP
sequencing to the traditional clone picking method, HTP
sequencing accelerates the discovery of specific binders [19]. This
earlier independent study supports our finding by demonstrating
the high correlation between abundances in the first round and
subsequent rounds of selection, clearly showing that HTP
sequencing could identify the highly enriched clones without the
need of additional selection rounds [19]. The higher resolution of
the selection pools enabled by HTP sequencing also allowed us to
characterize the enrichment process. Firstly, by demonstrating the
reduction in the number of unique peptides during biopanning
(Figure 3A), which is indicative of the enrichment of a subset of
phages. Secondly, by revealing that phage 1 was significantly
enriched to 80% of the sequenced population as early as round 3
(Figure 3B). Attaining this kind of quantitative data would not be
possible using random clone picking, since this method is limited
by the number of clones that can be analyzed. This means that it
will be improbable to achieve the sequencing depth similar to that
of HTP sequencing, making it more difficult to evaluate the degree
of enrichment of the selected clones.
Figure 6. Biacore sensograms showing the association of bacteria whole cell lysates with immobilized synthetic peptides. (A) Phage1
synthetic peptide (phage1-synpeptide) and scrambled peptide (phage1-synpeptide-Sc) were captured with the covalently bound streptavidin on the
CM5 chip. (B) Whole cell lysates of M. tb H37Rv with a total protein concentration of 100 mg/ml and 500 mg/ml were injected over the immobilised
peptides. To evaluated specificity whole cell lysates with a total protein concentration of 100 mg/ml from unrelated bacteria, (C) Escherichia coli
ER2738 (D) Corynebacterium xerosis (E) Streptococcus pyogenes (F) Staphylococcus aureus, were injected over the immobilised peptides. Changes in
surface plasmon resonance were monitored in real time and are shown in response units.
doi:10.1371/journal.pone.0077844.g006
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When we further characterized the binding specificity of phage
1 to pathogenic M. tb H37Rv, it was interesting to note that there
was no significant difference in the binding to all mycobacterium
species tested, with the exception of BCG which had a significantly
(p,0.01) higher binding signal. This data suggests that the phage 1
binds to a molecule conserved across the three mycobacterium
species.
A phage displaying the same peptide, CPLHARLPC, has
recently been isolated and characterized as binding to the
IV.C102 H1N1 monoclonal antibody and the swine-origin
influenza virus A sera [25]. This monoclonal antibody has
previously been demonstrated to bind to the type A H1N1
influenza strain epitopic peptide localized in residues 207–225 of
the hemagglutinin HA1 subunit [26]. However, there is no
sequence similarity between the IV.C102 monoclonal antibody
epitope (AIYHTENAYVSVVSSHYNR) on the hemagglutinin
protein and the peptide displayed by phage 1. Luchesse and
colleagues (2009) further characterized that peptide AIYHTENA
is the minimal determinant epitopic region required for IV.C102
binding [27], which only has two amino acids in common,
histidine and alanine, to the phage 1 displayed peptide.
Nevertheless, the phage 1 displayed peptide contains five
hydrophobic amino acids (out of nine), and the minimal epitopic
peptide of the IV.C102 antibody also includes four hydrophobic
amino acids (out of the eight). This may suggest that the
interaction of this peptide with either the IV.C102 H1N1
monoclonal antibody or mycobacteria is most likely via hydro-
phobic interactions.
There are reagent similarities, like the plastic polystyrene
microtiter wells, between the biopanning experiments and an
ELISA. It is possible that these similarities could contribute falsely
to apparent binding as previously discussed by others [28]. This
necessitates the use of a different method that does not include
these materials, to further validate intended target binding.
Indeed, when the peptide displayed by phage 1 was evaluated
on surface plasmon resonance technology, the results showed that
this peptide is able to associate with the M. tb H37Rv whole cell
lysate while its scrambled counterpart exhibited minimal binding
(Figure 6B). The diminished binding of this peptide when it is
scrambled shows that the phage1-synthetic peptide sequence is
important for its specific interaction with mycobacteria. Further-
more, this peptide showed no binding (Figure 6C–F) to unrelated
Figure 7. Biacore sensograms showing the association of protease digested M. tb lysate with immobilized synthetic peptides.
Biotinylated phage1 synthetic peptide (phage1-synpeptide) and biotinylated phage 1 scrambled peptide (phage1-synpeptide-Sc) were captured with
covalently bound streptavidin on a CM5 chip. Protease-digested whole cell lysate of M. tuberculosis H37Rv with a total protein concentration of
100 mg/ml was injected over the immobilised peptides. (B) shows tha control experiment using the undigested M. tuberculosis H37Rv whole cell
lysate. Changes in surface plasmon resonance were monitored in real time and are shown in response units.
doi:10.1371/journal.pone.0077844.g007
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bacteria that were tested which is indicative of specificity to
mycobacteria.
Mycobacteria have multiple possible binding partners for the
phage 1 displayed peptide. These potential ligands vary in their
nature, ranging from cell wall proteins, glycans and free lipids
[29]. In this work, we have demonstrated that the highly enriched
phage 1 peptide binds to a mycobacterial protein of approximately
15 kDa in size. However, the identification of the target protein
requires further validation.
In conclusion, our findings show that phage display combined
with HTP sequencing is a useful tool for the identification of
specific peptides to mycobacteria. Our results also indicate that
peptide CPLHARLPC is a good candidate to probe for a potential
biomarker for TB infection. However, the lack of specific
mycobacterium strain markers remains a limiting factor in TB
biomarker development. Notwithstanding, this is a proof-of-
concept study showing that this approach could be used to
identify additional peptides with better specificity for M. tb.
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